Remitting relapsing PLP-induced EAE Efficacy Model for MS Research
Proteolipid Protein (PLP) is a major protein component of CNS myelin. Sections of PLP, such as peptide fragment 139-151, are encephalitogenic to certain mouse strains. PLP injected in Swiss Jim Lambert (SJL) mice together with pertussis toxin (PT) will lead to remitting and relapsing demyelinating disease. Relapses are associated with epitope spreading, in which T cells react to secondary endogenous peptides that emerge as a consequence of the initial phase of myelin destruction. Remissions are associated with a temporary loss of inflammatory cells from the CNS.
MD Biosciences incorporates a range of in vivo measures and endpoint assessments that provide a robust data package that enable researchers to make critical decisions.
Pain behavior tests include dynamic weightbearing and Hargreaves to assess the distribution on each paw and sensitivity to heat.
Clinical score in the PLP-induced EAE model indicating the peaks of disease. The first phase of the disease begins around day 10 and subsides around day 25. On day 40 the relapse begins.
Review the complete dataset.